Excess length of stay and economic consequences of adverse events in Dutch hospital patients

Janneke Hoogervorst-Schilp, Maaike Langelaan, Peter Spreeuwenberg, Martine C de Bruijne, Cordula Wagner, Janneke Hoogervorst-Schilp, Maaike Langelaan, Peter Spreeuwenberg, Martine C de Bruijne, Cordula Wagner

Abstract

Background: To investigate the average and extrapolated excess length of stay and direct costs of adverse events (AEs) and preventable AEs in Dutch hospitals, and to evaluate patient characteristics associated with excess length of stay and costs.

Methods: Data of a large retrospective patient record review study on AEs was used. A stratified sample of 20 Dutch hospitals was included. Excess length of stay and costs attributable to AEs and preventable AEs were calculated and extrapolated to a national estimate. The association between patient characteristics and excess length of stay (and costs thereof) attributable to AEs and preventable AEs was investigated through multilevel linear regression analyses.

Results: A total of 2975 patient records were included in the analysis, of which 325 experienced one or more AEs. Hospital patients experiencing an AE stayed 5.11 (95% CI 3.91-6.30) more days in hospital and cost €2600 (95% CI €1968-€3232) more compared to those without an AE. There was no significant difference in days and costs between preventable and non-preventable AEs. Extrapolated to a national level, AEs cost more than €300 million, which was 1.3% of the national hospital care budget. Patients with hospital-acquired infections had a statistically significant longer length of stay compared to the reference group (patients with AEs on the cardiovascular system).

Conclusions: This study showed that AEs lead to substantial excess length of stay and increased costs. Special attention should be paid to patients with AEs due to an hospital-acquired infection.

References

    1. Zegers M, de Bruijne MC, Wagner C, Hoonhout LH, Waaijman R, Smits M, et al. Adverse events and potentially preventable deaths in Dutch hospitals: results of a retrospective patient record review study. Qual Saf Health Care. 2009;18(4):297–302. doi: 10.1136/qshc.2007.025924.
    1. Baker GR, Norton PG, Flintoft V, Blais R, Brown A, Cox J, et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. Cmaj. 2004;170(11):1678–1686. doi: 10.1503/cmaj.1040498.
    1. Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. 1991. Qual Saf Health Care. 2004;13(2):145–151. doi: 10.1136/qshc.2002.003822.
    1. Davis P, Lay-Yee R, Briant R, Ali W, Scott A, Schug S. Adverse events in New Zealand public hospitals I: occurrence and impact. N Z Med J. 2002;115(1167):U271.
    1. Soop M, Fryksmark U, Koster M, Haglund B. The incidence of adverse events in Swedish hospitals: a retrospective medical record review study. Int J Qual Health Care. 2009;21(4):285–291. doi: 10.1093/intqhc/mzp025.
    1. Vincent C, Neale G, Woloshynowych M. Adverse events in British hospitals: preliminary retrospective record review. BMJ. 2001;322(7285):517–519. doi: 10.1136/bmj.322.7285.517.
    1. Thomas EJ, Studdert DM, Burstin HR, Orav EJ, Zeena T, Williams EJ, et al. Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care. 2000;38(3):261–271. doi: 10.1097/00005650-200003000-00003.
    1. Wilson RM, Runciman WB, Gibberd RW, Harrison BT, Newby L, Hamilton JD. The quality in Australian health care study. Med J Aust. 1995;163(9):458–471.
    1. Ackroyd-Stolarz S, Read Guernsey J, Mackinnon NJ, Kovacs G. The association between a prolonged stay in the emergency department and adverse events in older patients admitted to hospital: a retrospective cohort study. BMJ Qual Saf. 2011;20(7):564–569. doi: 10.1136/bmjqs.2009.034926.
    1. Cihangir S, Borghans I, Hekkert K, Muller H, Westert G, Kool RB. A pilot study on record reviewing with a priori patient selection. BMJ Open. 2013;3:7. doi: 10.1136/bmjopen-2013-003034.
    1. Forster AJ, Kyeremanteng K, Hooper J, Shojania KG, van Walraven C. The impact of adverse events in the intensive care unit on hospital mortality and length of stay. BMC Health Serv Res. 2008;8:259. doi: 10.1186/1472-6963-8-259.
    1. Hoonhout LH, de Bruijne MC, Wagner C, Asscheman H, van der Wal G, van Tulder MW. Nature, occurrence and consequences of medication-related adverse events during hospitalization: a retrospective chart review in the Netherlands. Drug Saf. 2010;33(10):853–864. doi: 10.2165/11536800-000000000-00000.
    1. Ricciardi R, Roberts PL, Read TE, Hall JF, Marcello PW, Schoetz DJ. Which adverse events are associated with mortality and prolonged length of stay following colorectal surgery? J Gastrointest Surg. 2013;17(8):1485–1493. doi: 10.1007/s11605-013-2224-3.
    1. Sari AB, Sheldon TA, Cracknell A, Turnbull A, Dobson Y, Grant C, et al. Extent, nature and consequences of adverse events: results of a retrospective casenote review in a large NHS hospital. Qual Saf Health Care. 2007;16(6):434–439. doi: 10.1136/qshc.2006.021154.
    1. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301–306. doi: 10.1001/jama.1997.03540280039031.
    1. Ehsani JP, Duckett SJ, Jackson T. The incidence and cost of cardiac surgery adverse events in Australian (Victorian) hospitals 2003–2004. Eur J Health Econ. 2007;8(4):339–346. doi: 10.1007/s10198-006-0036-z.
    1. Hellsten EK, Hanbidge MA, Manos AN, Lewis SJ, Massicotte EM, Fehlings MG, et al. An economic evaluation of perioperative adverse events associated with spinal surgery. Spine J. 2013;13(1):44–53. doi: 10.1016/j.spinee.2013.01.003.
    1. Hoonhout LH, de Bruijne MC, Wagner C, Zegers M, Waaijman R, Spreeuwenberg P, et al. Direct medical costs of adverse events in Dutch hospitals. BMC Health Serv Res. 2009;9:27. doi: 10.1186/1472-6963-9-27.
    1. Hug BL, Keohane C, Seger DL, Yoon C, Bates DW. The costs of adverse drug events in community hospitals. Jt Comm J Qual Patient Saf. 2012;38(3):120–126.
    1. Kaushal R, Bates DW, Franz C, Soukup JR, Rothschild JM. Costs of adverse events in intensive care units. Crit Care Med. 2007;35(11):2479–2483. doi: 10.1097/01.CCM.0000284510.04248.66.
    1. Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013;33(4):383–391. doi: 10.1002/phar.1223.
    1. Kim MH, Lin J, Hussein M, Battleman D. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy. Curr Med Res Opin. 2009;25(12):3037–3047. doi: 10.1185/03007990903368716.
    1. Oderda GM, Evans RS, Lloyd J, Lipman A, Chen C, Ashburn M, et al. Cost of opioid-related adverse drug events in surgical patients. J Pain Symptom Manage. 2003;25(3):276–283. doi: 10.1016/S0885-3924(02)00691-7.
    1. Rottenkolber D, Hasford J, Stausberg J. Costs of adverse drug events in German hospitals--a microcosting study. Value Health. 2012;15(6):868–875. doi: 10.1016/j.jval.2012.05.007.
    1. Schneider PJ, Gift MG, Lee YP, Rothermich EA, Sill BE. Cost of medication-related problems at a university hospital. Am J Health Syst Pharm. 1995;52(21):2415–2418.
    1. Naessens JM, Campbell CR, Shah N, Berg B, Lefante JJ, Williams AR, et al. Effect of illness severity and comorbidity on patient safety and adverse events. Am J Med Qual. 2012;27(1):48–57. doi: 10.1177/1062860611413456.
    1. Baines R, Langelaan M, de Bruijne M, Spreeuwenberg P, Wagner C. How effective are patient safety initiatives? A retrospective patient record review study of changes to patient safety over time. BMJ Qual Saf. 2015;24(9):561–571. doi: 10.1136/bmjqs-2014-003702.
    1. Borghans I, Heijink R, Kool T, Lagoe RJ, Westert GP. Benchmarking and reducing length of stay in Dutch hospitals. BMC Health Serv Res. 2008;8:220. doi: 10.1186/1472-6963-8-220.
    1. Hakkaart-Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek: Methoden en standaard kostprijzen voor economische evaluatie in de gezondheidszorg (in Dutch): CVZ. 2010.
    1. Langelaan M, De Bruijne MC, Baines RJ, Broekens MA, Hammink K, Schilp J, et al. Monitor Zorggerelateerde Schade 2011/2012: dossieronderzoek in Nederlandse ziekenhuizen (in Dutch). Amsterdam/Utrecht: EMGO+ Instituut/VUmc, NIVEL. 2013.
    1. Twisk JW. Applied multilevel analysis: a practical guide: Cambridge University Press. 2006.
    1. Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ. 2012;184(1):37–42. doi: 10.1503/cmaj.110543.
    1. Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention. J Hosp Infect. 2009;73(4):305–315. doi: 10.1016/j.jhin.2009.04.019.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere